101. Epigenetic therapy for breast cancer
- Author
-
Bei Zhang, Corina Kohler, Fengfeng Cai, Xiao Yan Zhong, Weijie Chen, and Minghong Wang
- Subjects
Epigenomics ,Methyltransferase ,epigenetic therapy ,Antineoplastic Agents ,Breast Neoplasms ,Catalysis ,Article ,lcsh:Chemistry ,Inorganic Chemistry ,Breast cancer ,breast cancer ,medicine ,Humans ,Epigenetics ,Cancer epigenetics ,DNA (Cytosine-5-)-Methyltransferases ,Physical and Theoretical Chemistry ,Histone deacetylation inhibitors ,lcsh:QH301-705.5 ,Molecular Biology ,Spectroscopy ,biology ,Organic Chemistry ,Cancer ,DNA methylation inhibitors ,General Medicine ,DNA Methylation ,medicine.disease ,Computer Science Applications ,Histone Deacetylase Inhibitors ,Histone ,lcsh:Biology (General) ,lcsh:QD1-999 ,DNA methylation ,biology.protein ,Cancer research ,Female ,Epigenetic therapy - Abstract
Both genetic and epigenetic alterations can control the progression of cancer. Genetic alterations are impossible to reverse, while epigenetic alterations are reversible. This advantage suggests that epigenetic modifications should be preferred in therapy applications. DNA methyltransferases and histone deacetylases have become the primary targets for studies in epigenetic therapy. Some DNA methylation inhibitors and histone deacetylation inhibitors are approved by the US Food and Drug Administration as anti-cancer drugs. Therefore, the uses of epigenetic targets are believed to have great potential as a lasting favorable approach in treating breast cancer.
- Published
- 2011